The costs of large trials have led investigators to consider intermediate end points such as modification of risk factors or early manifestations of disease. For example, the degree of stenosis in coronary vessels has been measured directly by serial angiography.' B Mode ultrasound is a non-invasive method of examining the arterial wall for stenosis and plaques and for measuring the thickness of the intima-media complex. There is considerable interest in using these non-invasive measures as surrogate end points to evaluate new interventions. But are they any good?
Intima-media thickness Lines defining the intima-media complex in an artery (figs 1 and 2) can be identified and the distance between them corresponds closely with the intima-media thickness measured histologically, with differences of only 4% and 9% in the carotid and femoral arteries respectively. In healthy adults the intima-media thickness (IMT) ranges from 0-25 mm to 1-5 mm (mean (SD) 077 A difference of about 0 15 mm (for example, the difference between healthy and hypertensive subjects) can be clinically important; but such a difference can be produced by between or even within observer variation. The reliability of IMT measured by observers examining the same patients has 95% limits of agreement of ±013-015 mm between observers and ± 006-013 mm within observers.'5 Because measurement error is so large in relation to clinically important differences, any bias in measurement can lead to spurious findings. Measurement error between observers is greater than when the same observer looks at the same images. The implications are that if possible only one observer should be used, that observers must be blinded to the treatment received, and that it is essential to have standardisation of protocols and estimates of reliability in multicentre and long duration studies using several observers. Computer Lipid lowering may be associated with the angiographic appearances of "regression" (that is, an increased lumen or reduction in arterial obstruction): these changes, however, may not be equivalent to histopathological regression of atheroma.1 Complex interactions between arterial wall damage, the flow characteristics of vessels, and blood constituents determine the risk of clinical events. IMT gives an indication of only one aspect of the pathophysiological process and is not equivalent to angiographic "regression".
Use of IMT as an end point in clinical trials
In conventional trials that use clinical events as end points thousands of patients must be studied to obtain adequate statistical power. The major advantage of using IMT is that every patient randomised produces an end point (provided that they survive) and adequate statistical power is achieved with much smaller sample sizes. This may be attractive in testing promising drugs before carrying out much larger studies that use disease events as end points.12 CURRENT 
EXPERIENCE
Several randomised controlled trials of lipid lowering drugs and antihypertensives are now underway with IMT as a major trial end point. The entry criteria for these trials include the presence of lesions detected by ultrasound that are potentially reversible (that is, plaques or an above average IMT or both), which halves the patients available for a trial. '2 One study comparing colestipol and niacin with placebo has reported findings at 4 years4 among a subset of patients. In patients on treatment IMT got smaller during the first 2 years (-005 mm) and stabilised over the subsequent 2 years (although vessel lumens in the treated group got smaller) compared with a placebo group in whom IMT increased (+ 004 mm). The In trials of patients at high risk of cardiovascular disease it is likely that some will die and will not have an IMT measurement. Death rates can be as high as 10% per year in high risk, older subjects and this level of loss could reduce the comparability of treatment and placebo groups and lead to bias in IMT end points.
GENERALISABILITY
The generalisability of trial findings from a carefully selected study group to the more typical patients seen in primary care and district hospitals is vital if a trial is to have clinical value and lead to changes in medical practice. The extremely large international studies of infarct survival (ISIS) after thrombolysis have had a major impact because they were generalisable to patients in many different clinical settings.
Conclusions
The current interest in using IMT as a trial end point for lipid lowering drugs and other treatments for atheroma is logical if it is assumed that changes in IMT correlate with the rate at which lipid-rich plaques are likely to progress to fissure and clinical events. The evidence to support such an assumption is not available. Very few plaques seem to be dangerous and likely to progress to clinical events. Consequently treatments that reduce plaque size, volume, or IMT may have very little effect on clinical events and vice versa.
Clinical decision making is based on efficacy, side effects and costs of treatment. How much should we be prepared to pay for a reduction of 005 mm in carotid IMT? The value of IMT end points is uncertain given current understanding of the meaning of the measurement. Large scale prospective epidemiological studies using ultrasound are required to examine the feasibility, utility, and importance of IMT. If epidemiological studies support the prognostic value of IMT, these end points will be of value in early, small scale trials of promising drugs that aim to reduce the rate of progression of atheroma. Ultrasound measures may also be of value in assessing the severity of atheroma and in defining high risk groups for intervention. Larger trials using clinical end points will always be required to establish the clinical benefits, risks, and costs of treatments and thereby change clinical practice.
